CBD and Cognitive Aging: Why Trials in Young Adults Cannot Establish Benefit in Older Adults
A 2025 mini review identified a central gap in CBD cognition research: much of the human evidence concerns young, healthy adults and acute dosing. That evidence cannot establish preservation of cognition in older adults over time.
Preclinical promise and clinical evidence differ
The review described encouraging preclinical work involving neurogenesis and cognitive performance. Animal or laboratory changes can motivate human research, but they do not show that an older patient will retain memory, independence or daily function. Those require appropriate human outcomes.
Age may change the exposure-response question
The authors highlighted age-related changes in the endocannabinoid system and low, variable oral bioavailability. Consequently, the same labeled amount does not resolve how exposure or response compares across age groups. This is a research concern, not a validated formula for adjusting a person's dose.
Acute performance is not long-term prevention
A short cognitive assessment after one administration answers a different question from preventing age-related decline. The review called for controlled older-adult trials with standardized cognition measures and supporting neuroimaging or biomarkers. A biological signal would still need connection to a meaningful clinical outcome.
Interpreting the evidence
For a cognitive-aging claim, check the participants' ages, treatment duration and outcome. This review identifies why extrapolation is uncertain; it does not establish CBD as a preventive treatment for dementia or a proven cognitive enhancer in older people.
Related reading: interpreting cannabis tolerance claims.
Research reference
Alicja Anna Binkowska; Agnieszka Mateja; Natalia Jakubowska (2025). Cannabidiol (CBD) and cognitive function in older adults: a mini review. Frontiers in Psychiatry. doi:10.3389/fpsyt.2025.1646151.
This analysis draws on the supplied review’s abstract and introductory material.
